Peptide therapy TikTok claims: separating signal from noise

What did @justagrownwoman actually say?

The creator asked men to share their kisspeptin results for libido, described it as working "in the brain" for hypoactive sexual desire disorder (HSDD), and claimed men respond better than women to libido peptides like kisspeptin and PT-141. She also floated the question of whether kisspeptin could help women in menopause, framed as her own curiosity rather than a firm claim. The video ends with an affiliate link to Ion Peptides.

To her credit, she kept it conversational and didn't make specific dosing claims or guarantee outcomes. She acknowledged women have "so much more ingredients that are fighting against us," which is a loose but not entirely wrong way of describing the hormonal complexity of female sexual response. The affiliate disclosure was present, which is more transparency than most peptide TikToks offer.

Does the science back this up?

Partially, yes. Kisspeptin's role in sexual brain circuitry is real and reasonably well-established. The claim that it works "in the brain" is accurate at a mechanistic level.

Kisspeptin is a neuropeptide encoded by the KISS1 gene. It acts primarily on the hypothalamus, stimulating gonadotropin-releasing hormone (GnRH) release, which then drives LH and FSH secretion. Research by Dhillo et al. (2005, Journal of Clinical Endocrinology and Metabolism) established that kisspeptin-54 infusion in healthy men significantly elevated LH and testosterone. More relevantly to libido, Comninos et al. (2017, JCI Insight) found that kisspeptin-54 infusion enhanced sexual brain processing in men with HSDD, as measured by fMRI, and improved mood associated with sexual stimuli. That's a real finding in a real journal, not a bro-science forum post.

The menopause angle she raised is speculative but not baseless. Kisspeptin neurons are sensitive to estrogen feedback, and their dysregulation is implicated in menopausal hot flashes and hormonal disruption (Rance et al., 2013, Journal of Neuroendocrinology). Whether exogenous kisspeptin supplementation translates to improved libido in postmenopausal women remains under-studied in clinical trials.

What did they get wrong (or right)?

The claim that men respond "so much better" to libido peptides than women is an overstatement. The existing kisspeptin libido data is almost entirely in men, so the comparison is premature, not proven.

The Comninos 2017 trial enrolled men with HSDD. There is no equivalent-scale clinical trial in women showing kisspeptin fails for libido, which means the creator is filling a data gap with a confident-sounding generalization. That's a meaningful difference. She's not wrong that female sexual dysfunction is harder to treat and involves more physiological variables, but saying men respond "so much better" implies comparative data that doesn't yet exist in published literature.

She also loosely groups kisspeptin with PT-141 (bremelanotide) as if they work the same way. They don't. PT-141 acts on melanocortin receptors. Kisspeptin acts on GnRH pathways. Both involve central nervous system mechanisms, but the receptor targets, downstream effects, and clinical evidence bases are distinct. Conflating them as interchangeable libido peptides is an oversimplification that could mislead viewers.

• Got right: kisspeptin acts centrally, not peripherally
• Got right: it has genuine research backing for HSDD in men
• Got wrong: the men-vs-women efficacy comparison lacks comparative trial data
• Got wrong: PT-141 and kisspeptin are not equivalent mechanisms

What should you actually know?

Kisspeptin research is genuinely interesting, but it is not an approved treatment in the U.S. for HSDD or any other condition as of 2024. What's sold by peptide research companies is typically unregulated, not pharmaceutical-grade, and has no FDA-cleared dosing protocol for human use. That matters.

The affiliate link in the video connects to a research peptide supplier. Peptides sold this way are not compounded drugs from licensed pharmacies, they're not equivalent to what was used in clinical trials, and quality control varies enormously. If you're genuinely dealing with low libido, that's a conversation for a clinician who can assess your hormone panel, medications, and health history. Kisspeptin may one day be part of that conversation in a regulated context. Right now, it's not there yet.

For anyone curious about the menopause angle: the research exists mostly in animal models and mechanistic studies. It's a legitimate area of inquiry, but it is speculative to suggest kisspeptin supplementation would benefit menopausal women based on current evidence.